Introduction
============

Atherosclerotic renal artery hypertension is reported in almost 7% of adults older than 65 years[@B1] and is associated with cardiovascular events, and may double risk of mortality[@B2]. In the 1990s, radiological angioplasty began to replace surgical revascularization. Galaria et al. showed that percutaneous and open renal revascularization had equivalent long-term functional outcomes[@B3]. Over time, the less-invasive procedure became more accessible.

Most cases of atherosclerotic renovascular disease (ARVD) are located in the ostium, and are extensions of calcified aortic plaques[@B4]. These lesions tend to return to their original shape with balloon angioplasty alone. Stent placement might also provide additional force to increase the rates of technical success[@B5] and to reduce the rate of restenosis at 6 months after the initial procedure[@B6]. Intervention with stents has become a standard procedure; in patients with stenosis of the renal artery, placement of a stent is likely to be the initial form of treatment. However, there is limited evidence to support revascularization over medical therapy for patients with atherosclerotic renal artery stenosis[@B7], [@B8].

Natural history
===============

Retrospective studies previously reported that renal artery lesions might progress to severe stenosis and ultimately to renal artery occlusion[@B9]. Michael et al. performed a prospective study that reported that the progression of renal artery disease was a frequent occurrence with an annual rate of progression of renal artery lesions reported to be 7%[@B10]. However, at the time of these studies, statins were being used in fewer patients. A retrospective study of the effects of statins on the progression of ARVD has shown that the use of statins reduces the risk of progression and the development of ARVD[@B11]. Another prospective population-based study reported that the progression to significant ARVD was observed in only 4.0% during 8 years of follow-up (annualized rate, 0.5% per year), and no case of ARVD progressed to occlusion[@B12].

Dissociation between arterial patency and function
==================================================

Hypertension and renal artery stenosis are not necessarily renovascular hypertension. Essential hypertension and clinically silent renal artery stenosis often coexist, and essential hypertension also coexists with renovascular hypertension[@B13]. This is why blood pressure control does not always improve after stenting.

Renal injury distal to an atherosclerotic renovascular obstruction is due to multiple intrinsic factors producing parenchymal tissue injury ([Fig. 1](#F1){ref-type="fig"})[@B14]. Non-traditional mediators of ARVD such as inflammatory pathways, reactive oxygen species production, ischemia/reperfusion damage and modulation of matrix turnover have been proposed as causes of the renal failure related to ARVD[@B15]. This complexity of the pathophysiology might explain why the severity of the stenosis is not correlated with renal dysfunction.

Clinical data support dissociation of improved renal artery patency from clinical outcome in patients with atherosclerotic renal artery stenosis; this may illustrate the effects of irreversible injury on the post stenotic kidney. A prospective clinical study reported by Wright et al. showed absence of a correlation between renal artery anatomy and baseline renal function or functional outcome, and a good correlation between renal functional outcome and proteinuria; these findings suggest that renal parenchymal damage is a major determinant of renal dysfunction and outcome rather than the severity of the renal artery stenosis in ARVD[@B16]. Radermacher et al. reported that the mean arterial pressure did not decrease by 10 mmHg or more after revascularization and renal function declined in most patients with ARVD that had high resistance-index values before revascularization[@B17]. Chrysochou et al. showed a correlation between baseline proteinuria and decline in estimated glomerular filtration rate (GFR) with time after revascularization[@B18]. Therefore, post stenotic renal injury can lead to renal parenchymal injury reflected by high intrarenal resistance and/or the presence of proteinuria. Proteinuria and other factors involved in intrarenal resistance are predictors of a poor outcome after renal revascularization in ARVD.

When patients with chronic kidney disease undergo renal angioplasty with/without stent placement, the response with regard to renal function can be negative as well as positive. Positive responses include improvement of renal function, and stabilization or attenuation of declining renal function, as expected. However, sometimes declining renal function is accelerated after revascularization. Possible causes of these adverse outcomes include contrast induced nephropathy, atheroembolism, and restenosis or stent thrombosis[@B19]. The administration of contrast might increase the risk of acute renal dysfunction, especially in patients that have preexisting renal impairment. An ex vivo study reported that each manipulation of atheroma specimens, from simply advancing the guidewire through the atherosclerotic lesion to positioning and deploying the Wallstent, releases thousands of fragments, and that these atherosclerotic fragments are of sufficient size to create vascular occlusion and initiate significant renal parenchymal damage[@B20]. Currently, there is no way to predict positive or negative responses after revascularization.

Factors favoring medical therapy
================================

ARVD is a cardiovascular condition that is associated with renal artery stenosis. The nature of this disorder suggests that a systemic approach is necessary to provide cardiovascular protection. Previously, statin therapy was discussed as a method of altering the natural history of ARVD[@B11]. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers effectively reduce blood pressure in patients with renovascular disease. In addition, a population-based cohort study of over 3,500 patients with ARVD in Canada found that angiotensin inhibitors could cause acute renal toxicity in a small subset of vulnerable patients; however, they still improved the cardiovascular and renal outcomes in patients with ARVD, but at the expense of acute renal toxicity[@B21].

Recently three randomized controlled trials have been performed: the Stent Placement and Blood Pressure and Lipid-lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR) trial, the Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial, and the Cardiovascular Outcomes in Renal Artherosclerotic Lesions (CORAL) trial ([Table 1](#T1){ref-type="table"}). Two large randomized trials of intervention vs. medical therapy showed negative results for the intervention. The last trial is under way. The STAR trial was a European multicenter trial that enrolled 140 patients with ostial renal artery stenosis greater than 50%, blood pressure controlled to less than 140/90 mmHg, and creatinine clearance 15 to 80 mL/min[@B7]. All patients received angiotensin blocking agents and a statin, regardless of their lipid levels. After a 2-year interventional period, no difference was observed in the decline of renal function, the degree of blood pressure control, and the rates of cardiovascular morbidity and death. Investigators in the ASTRAL trial enrolled 806 patients with at least one stenotic renal artery considered suitable for balloon angioplasty, stenting, or both in their international, multicenter trial[@B8]. The mean estimated GFR was 40 mL/min, and most of the patients were on statin and angiotensin blocking therapy. At a mean follow-up of 33.6 months, no difference was noted between the treatment groups in the decline of renal function or blood pressure control, and the renal function worsened slightly in both groups. Most of the enrolled patients in the two clinical trials had relatively asymptomatic atherosclerotic renal artery stenosis. Therefore, the practice of indiscriminately performing revascularization, without strong evidence, is no longer acceptable. The CORAL trial is an ongoing multicenter randomized controlled trial in the United States[@B22]. It is still enrolling patients that have drug-resistant hypertension or a GFR \< 60 mL/min. It is using a standardized medical protocol to control blood pressure, and embolic protection devices during procedures are encouraged.

Thus far, intervention has not been recommended if renal function has remained stable over the past 6 to 12 months and if hypertension can be controlled medically. According to a clinical classification of atherosclerotic renal artery stenosis with guidelines for vascular intervention of surveillance published in 2008 by the Atherosclerotic Peripheral Vascular Symposium[@B23], additional recommendations favoring medical therapy were as follows: very advanced age and/or limited life expectancy, extensive co-morbidities that make revascularization too risky, high risk for or previous experience with atheroembolic disease, and other concomitant renal parenchymal diseases that cause progressive renal dysfunction (e.g., interstitial nephritis, diabetic nephropathy)[@B23]. They also recommended factors favoring medical therapy and intervention as follows: progressive decline in GFR during treatment of systemic hypertension, failure to achieve adequate blood pressure control with optimal medical therapy (medical failure), rapid or recurrent decline in the GFR in association with a reduction in systemic pressure, decline in the GFR during therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and recurrent congestive heart failure in a patient in whom the adequacy of left ventricular function does not provide an explanation[@B23]. The best evidence supporting intervention is for bilateral stenosis with \"flash\" pulmonary edema, but the evidence is from retrospective studies[@B24]-[@B26].

Conclusion
==========

The aim of treatment for ARVD should include the prevention of cardiovascular and/or renal events. Treatment of patients with ARVD should include consideration of the following factors: age, co-morbidity, blood pressure, renal function, and kidney size. The results of two recent studies suggest that patients with ARVD and stable renal function can be controlled medically. Intervention should be considered only in patients with ARVD and rapidly progressive cardiac or renal dysfunction. However, these conditions also increase the risk of complications related to revascularization procedures. Both the risks and potential long-term benefits of intervention should be considered. The results of the CORAL and the post hoc analysis of ASTRAL might provide additional evidence for revascularization.

![Mechanisms of Renal Damage Associated with Atherosclerotic Renal Artery Stenosis. These mechanisms include an interaction among increased oxidative stress, immune responses, inflammation, immune responses, and angiotensin II/endothelin, which impair renal function, induce endothelial and epithelial dysfunction and injury, and may lead to irreversible scarring. Ox LDL, oxidized low-density lipoprotein cholesterol.\
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STAR, Stenosis of the Renal Rrtery; ASTRAL, Angioplasty and Stenting for Renal Artery Lesions; CORAL, Cardiovascular Outcomes in Renal Artherosclerotic Lesions; GFR, glomerular filtration rate; BP, blood pressure; PTA, percutaneous transluminal angioplasty.
